NEJM Submission Process

This page is about workflow after upload.

Use it when you want to understand:

• what happens once the manuscript enters the NEJM system
• what early editorial triage is really testing
• how to interpret quiet periods, review movement, and review-stage slowdowns
• what usually causes an NEJM paper to die before or during review

If you still need to decide whether the package is ready, that belongs on the submission-guide page.

The process usually feels easiest when the manuscript already arrives with:

• a broad clinical consequence that is obvious quickly
• a title, abstract, and first display that all support the same main claim
• an evidence package that feels decisive enough for a flagship screen
• reporting and disclosure materials that already look stable

If those pieces are soft, the process can feel abrupt because the file will fail before external review becomes the main issue.

NEJM triage is not mainly testing whether the study is interesting.

It is testing whether:

• the paper is broad enough for a top general clinical journal
• the consequence is important enough to matter now
• the evidence is decisive enough to justify reviewer time
• the manuscript looks like it was actually prepared for this audience
• the paper should stay in the flagship conversation rather than move to a narrower clinical home

That is why a fast rejection here often means "not broad or decisive enough for NEJM," not "bad study."

Authors should think in stages:

• the earliest period is mostly editorial-fit and decisiveness judgment
• movement into review usually means the hardest broad-clinical screen has been cleared
• later slowdowns often reflect methodological, statistical, or consequence-level scrutiny rather than admin delay

The practical point is that the real risk sits early. If the manuscript survives that first editorial read, the conversation usually shifts from audience fit to whether the evidence package fully carries the clinical claim.

NEJM has specific formatting requirements from the initial submission, unlike Nature which accepts format-free first submissions.

Required materials:

• manuscript file formatted to NEJM specifications (double-spaced, numbered pages)
• structured abstract (250 words maximum, with Background, Methods, Results, and Conclusions)
• cover letter
• all figures and tables (separate files, publication quality)
• ICMJE Uniform Disclosure Forms for every author
• trial registration number (mandatory for any interventional study)
• data sharing plan
• IRB/ethics committee approval documentation

Two NEJM-specific requirements that catch authors off guard:

1. The word limit is strict. Original Articles are limited to 2,700 words of text (excluding abstract, references, tables, and figure legends). This is shorter than JAMA's 3,000-word limit and much shorter than The Lancet's more flexible allowance. If your manuscript is 4,000 words, you can't just submit it and hope. You need to cut it first.

2. Figures must be publication-ready from the start. NEJM doesn't accept embedded figures in the manuscript file for initial submission. Each figure needs its own file, properly formatted. This is different from The Lancet and Cell, which accept embedded figures initially.

Those details matter because NEJM reads package discipline as part of manuscript discipline. A paper that sounds major but arrives operationally loose is already fighting the wrong battle.

NEJM's editorial bar is specific. Understanding it helps you decide whether to submit here or elsewhere.

1. Does this change what doctors do tomorrow morning?

This is the real test. NEJM isn't interested in incremental advances in understanding disease mechanisms. It wants papers where the evidence is strong enough that a practicing physician would change their clinical approach after reading the article. If the conclusion is "more research is needed" or "this provides insights into pathophysiology," the paper probably belongs in a specialty journal.

2. Is the evidence from a trial or definitive study design?

NEJM has a strong preference for randomized controlled trials, large prospective cohort studies, and rigorous clinical investigations. Retrospective analyses, small case series, and observational studies face a much higher bar. There are exceptions, but the default is that NEJM publishes trials.

3. Is the sample size adequate for the claim?

NEJM's process is especially unforgiving when the package looks smaller than the conclusion. If your trial is underpowered for its primary endpoint, or the analysis plan does not fully support the strength of the claim, the manuscript will feel less decisive very early.

4. Is this written for a generalist?

NEJM's readership is primarily practicing physicians across all specialties. A paper about a novel immunotherapy regimen needs to be understandable to a family physician, not just an oncologist. If the abstract requires specialist vocabulary to parse, the editorial team will notice.

NEJM's cover letter has a specific purpose that differs from other journals. At The Lancet, you're arguing global relevance. At NEJM, you're arguing clinical decisiveness.

Your NEJM cover letter should:

• state the main finding in one sentence
• describe the study design and sample size
• explain what clinical practice would change based on this evidence
• confirm that the manuscript isn't under consideration elsewhere
• list any previous publications from the same trial or dataset

Don't use the cover letter to explain the background of the disease or to argue that the topic is important. The editors already know. They want to know whether this specific paper, with this specific evidence, changes practice.

NEJM occasionally publishes translational science, but only when the clinical implication is immediate and specific. A paper showing a new molecular pathway in cancer is better suited to Nature Medicine or Cell. A paper showing that targeting that pathway produces remission in a Phase 2 trial belongs at NEJM.

A well-conducted RCT comparing Drug A to Drug B for a condition where the standard of care hasn't changed in a decade is interesting. But if the effect size is modest and the clinical implication is "Drug A is slightly better in some patients," that's more likely a specialty journal paper. NEJM wants results that rewrite guidelines.

NEJM's 250-word abstract limit is strict. Authors who are used to writing 300 to 350 word abstracts for other journals often submit abstracts that are over the limit or that sacrifice clarity for completeness. At NEJM, the abstract should lead with the result, not the methods. If your first sentence describes the study design rather than what you found, rewrite it.

NEJM reviewers and editors are allergic to overclaiming. If your trial shows non-inferiority but you frame it as superiority, or if your 12-month follow-up is presented as evidence of long-term benefit, the paper loses trust immediately.

NEJM Evidence launched as a companion journal with a broader scope for clinical research that doesn't quite reach the NEJM flagship bar. When papers are rejected from NEJM, authors are sometimes invited to transfer to NEJM Evidence. The transfer preserves the reviews, which speeds up the decision at the receiving journal.

If you're uncertain whether your paper reaches NEJM's bar, consider whether NEJM Evidence might be the more realistic target. That is the practical implication of the process: a strong paper can still be wrong for the flagship without being wrong for the NEJM ecosystem.

• NEJM journal page
• NEJM submission guide
• Is NEJM a Good Journal?
• How to Avoid Desk Rejection at NEJM
• NEJM impact factor